title: Therapy-related leukemia with Inv(16)(p13.1q22) and type D CBFB/MYH11 developing after exposure to irinotecan-containing chemoradiotherapy.
abstract: A 40-year-old woman developed therapy-related acute myeloid leukemia (t-AML) with inv(16)(p13.1q22) and a rare type D form of core-binding factor β-subunit gene-myosin heavy chain 11 gene (CBFB-MYH11) fusion transcript approximately 2.5 years after receiving chemoradiotherapy for uterine cervical cancer. t-AML with inv(16)(p13.1q22) and rare non-type A CBFB-MYH11 typically develops after exposure to a topoisomerase II inhibitor, with a short period of latency of one to five years. As the patient had no history of exposure to topoisomerase II inhibitors, among her previously used chemotherapeutics, the topoisomerase I inhibitor, irinotecan, was speculated to be the most plausible cause of t-AML in this case. The present case suggests that irinotecan may cause t-AML resembling that associated with topoisomerase II inhibitors.
authors: Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan.
authors: Hiroki
authors: H
authors: Akiyama
authors: Masahide
authors: M
authors: Yamamoto
authors: Chizuko
authors: C
authors: Sakashita
authors: Yoshihiro
authors: Y
authors: Umezawa
authors: Tetsuya
authors: T
authors: Kurosu
authors: Naomi
authors: N
authors: Murakami
authors: Osamu
authors: O
authors: Miura
mesh_terms: D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D059248:Chemoradiotherapy / Q000009:adverse effects*; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics; D005260:Female; D006801:Humans; D000077146:Irinotecan; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000235:genetics / Q000378:metabolism; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; C095514:CBFbeta-MYH11 fusion protein; D015514:Oncogene Proteins, Fusion; D000077146:Irinotecan; D002166:Camptothecin